| Item Type | Name |
|
Concept
|
Maximum Tolerated Dose
|
|
Academic Article
|
Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.
|
|
Academic Article
|
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.
|
|
Academic Article
|
Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.
|
|
Academic Article
|
Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.
|
|
Academic Article
|
Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.
|
|
Academic Article
|
Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.
|
|
Academic Article
|
Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome.
|
|
Academic Article
|
Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.
|
|
Academic Article
|
Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.
|
|
Academic Article
|
Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia.
|
|
Academic Article
|
Phase I study of bortezomib in refractory or relapsed acute leukemias.
|
|
Academic Article
|
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
|
|
Academic Article
|
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.
|
|
Academic Article
|
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.
|
|
Academic Article
|
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
|
|
Academic Article
|
Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
|
|
Academic Article
|
Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.
|
|
Academic Article
|
A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis.
|
|
Academic Article
|
Farnesyl transferase inhibitor R115777 in myelodysplastic syndrome.
|
|
Academic Article
|
Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.
|
|
Academic Article
|
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
|
|
Academic Article
|
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia.
|
|
Academic Article
|
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.
|
|
Academic Article
|
Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia.
|
|
Academic Article
|
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
|
|
Academic Article
|
Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study.
|
|
Academic Article
|
Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.
|
|
Academic Article
|
KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.
|
|
Academic Article
|
Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.
|
|
Academic Article
|
Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia.
|
|
Academic Article
|
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
|
|
Academic Article
|
Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome.
|